Business Wire

2025 Thales Data Threat Report Reveals Nearly 70% of Organizations Identify AI’s Fast-Moving Ecosystem as Top GenAI-Related Security Risk

20.5.2025 09:00:00 CEST | Business Wire | Press release

Share

73% are investing in AI-specific security tools with either new or existing budgets. Malware remains top attack type since 2021; phishing rises to second, ransomware drops to third. 60% identified future decryption of today’s data and future encryption compromise as major concerns among quantum computing security threats.

Thales today announced the release of the 2025 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey conducted by S&P Global Market Intelligence 451 Research of more than 3,100 IT and security professionals in 20 countries across 15 industries. This year’s report found that nearly 70% of organizations view the rapid pace of AI development1 —particularly in generative AI—as the leading security concern related to its adoption, followed by lack of integrity (64%) and trustworthiness (57%).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520290850/en/

©Thales

The 2025 Thales Data Threat Report results reveal a major focus on the transformative impact of AI, especially GenAI, which relies heavily on high-quality, sensitive data for functions like training, inference, and content generation. As agentic AI emerges, ensuring data quality becomes even more critical for enabling sound decision-making and actions by AI systems. Many organizations are already adopting GenAI, with a third of respondents indicating it is either being integrated or is actively transforming their operations.

Organizations Embrace GenAI, Taking on Greater Security Risks Amid Rapid Adoption

As GenAI introduces complex data security challenges and offers strategic opportunities to strengthen defenses, its growing integration marks a shift among organizations from experimentation to more mature, operational deployment. While most respondents said rapid adoption of GenAI is their top security concern, respondents in the more advanced stages of AI adoption aren’t waiting to fully secure their systems or optimize their tech stacks before forging ahead. Because the drive to achieve rapid transformation often outweighs efforts to strengthen organizational readiness, these organizations may be inadvertently creating their own biggest security vulnerabilities.

“The fast-evolving GenAI landscape is pressuring enterprises to move quickly, sometimes at the cost of caution, as they race to stay ahead of the adoption curve,” Eric Hanselman, Chief Analyst at S&P Global Market Intelligence 451 Research, said. “Many enterprises are deploying GenAI faster than they can fully understand their application architectures, compounded by the rapid spread of SaaS tools embedding GenAI capabilities, adding layers of complexity and risk.”

Seventy-three percent of respondents report investing in AI-specific security tools, either through new budgets or by reallocating existing resources. Those prioritizing AI security are diversifying their approaches: over two-thirds have acquired tools from their cloud providers, three in five are leveraging established security vendors, and nearly half are turning to new or emerging startups. Notably, security for generative AI has quickly risen as a top spending priority, securing the second spot in ranked-choice voting, just behind cloud security. This shift underscores the growing recognition of AI-driven risks and the need for specialized defenses to mitigate them.

Data Breaches Show Modest Decline, Though Threats Remain Elevated

While data breaches remain a significant concern, their frequency has slightly decreased over the past few years. In 2021, 56% of surveyed enterprises reported experiencing a breach, but that figure has dropped to 45% in 2025. Additionally, the percentage of respondents reporting a breach within the last 12 months has fallen from 23% in 2021 to just 14% in 2025.

Malware continues to lead as the most prevalent threat, maintaining its top position since 2021. Phishing climbed to second place, overtaking ransomware, which now ranks third. When it comes to the most concerning threat actors, external sources dominate—hacktivists hold the top spot, followed by nation-state actors. Human error, while still significant, has dropped to third, down one position from the previous year.

Vendors Pressed on Post-Quantum Readiness as Encryption Strategies Are Reassessed

The 2025 Thales Data Threat Report reveals that most organizations are increasingly concerned about quantum-related security risks. The top threat, cited by 63% of respondents, is future encryption compromise—the risk that quantum computers could eventually break current or future encryption algorithms, exposing data once considered secure. Close behind, 61% identified key distribution vulnerabilities, where quantum advancements could undermine the secure exchange of encryption keys. Additionally, 58% highlighted the “harvest now, decrypt later” (HNDL) threat, where encrypted data intercepted today could be decrypted in the future. In response, half of organizations are assessing their encryption strategies, and 60% are actively prototyping or evaluating post-quantum cryptography (PQC) solutions. Only one-third, however, are placing their trust in telecom or cloud providers to manage the transition.

“The clock is ticking on post-quantum readiness. It’s encouraging that three out of five organizations are already prototyping new ciphers, but deployment timelines are tight and falling behind could leave critical data exposed,” Todd Moore, Global Vice President, Data Security Products at Thales, said. “Even with clear timelines for transitioning to PQC algorithms, the pace of encryption change has been slower than expected due to a mix of legacy systems, complexity, and the challenge of balancing innovation with security.”

While this year’s survey results indicate improvements in security posture, much more is needed to elevate operational data security to fully support the capabilities of emerging technologies such as GenAI and to pave the way for future innovations.

For more information please join our webinar hosted by Eric Hanselman, Chief Analyst at S&P Global 451 Research.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

1 This finding relates to the fast changes in the GenAI ecosystem which encompasses the full set of vendors and technologies in GenAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520290850/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye